Q162 – 174: GVHD Prophylaxis

*ATG and Campath
If ATG or Campath were ordered for GVHD prophylaxis prior to or after Day 0, report these drugs in the Additional Drugs Given in the Peri-Transplant Period section of the Pre-TED (2400) Form. Do not report these drugs in the GVHD Prophylaxis section.

Questions 162 – 172: Specify drugs (check all that apply)

After allogeneic HCT, specific immunosuppressive therapy may be administered to prevent GVHD or to immunosuppress the host marrow, thereby promoting engraftment of the donor stem cells. Most transplant centers have specific GVHD prophylaxis protocols and graft rejection protocols. Planned agents a recipient receives as a result of these protocols should be included in this section. This answer does not have to match what is reported on the Post-Infusion Follow-Up (2100) Form.

Specify the planned GVHD prophylaxis. Select all that apply.

If the planned GVHD prophylaxis is Abatacept, Cyclophosphamide, or Methotrexate, report the planned start date, the total number of planned doses, and the total planned prescribed dose, along with the unit of measurement.

The prophylactic drug options listed on the form are intended to be administered in a systemic or oral form. If the recipient received one of the listed drugs in a topical form, select the Other agent option and specify the drug and route of administration.

Do not report product manipulations for GVHD prophylaxis. Manipulations / interventions for GVHD prophylaxis are captured below.

If the recipient did not receive GVHD prophylaxis, select None.

If GVHD prophylaxis is used for a syngeneic (monozygotic or identical twin) or autologous HCT, attach a copy of the source document using the attachment feature in FormsNet3^SM.

!Product Manipulation for GVHD Prophylaxis
Product manipulation is not captured anywhere else on the Pre-TED (2400) Form and any manipulation done for GVHD Prophylaxis should be reported below. An example of product manipulation for GVHD prophylaxis is T-cell depletion.

Questions 173 – 174: Specify intervention (check all that apply)

Specify and product manipulations or interventions performed for GVHD prophylaxis. If Other intervention is selected, specify the intervention.

If interventions for GVHD prophylaxis were not completed, select None.

Section Updates:

Question Number	Date of Change	Add/Remove/Modify	Description	Reasoning (If applicable)
.	.	.	.	.

Copyright © 2004-2025 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.